More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$482579546
EPS
-2.64
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.798064
Previous close
$9.53
Today's open
$9.35
Day's range
$8.19 - $9.35
52 week range
$2.96 - $40.37
show more
CEO
Linda Marbn
Employees
231
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
58142114
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Capricor Stock Rises: What's Going On?
Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are rising Tuesday. Traders seemingly position ahead of the FDA's pending decision on its Duchenne muscular dystrophy therapy, deramiocel.
Benzinga • an hour ago

Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss
Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are trading higher Wednesday despite the company missing earnings per share estimates in its third-quarter results Tuesday after the market closed.
Benzinga • Nov 11, 2026

Capricor Therapeutics Q3 Earnings Call Highlights
Capricor Therapeutics NASDAQ: CAPR is awaiting a Nov. 22 Food and Drug Administration decision on Deramiocel for Duchenne muscular dystrophy, as the company prepares for a potential launch while reporting a wider third-quarter loss.
MarketBeat • Nov 11, 2026

Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 11, 2026

Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.
GlobeNewsWire • Nov 10, 2026

Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the abstract presenting cardiac results from the Company's HOPE-3 Phase 3 trial of Deramiocel in Duchenne muscular dystrophy (DMD) received the Outstanding Research Award in Pediatric Cardiology at the American Heart Association (AHA) Scientific Sessions 2026 on Saturday, November 7, in Chicago. The presentation included new cardiac MRI data on myocardial fibrosis, measured by late gadolinium enhancement (LGE), and a comparison with matched patients not treated with Deramiocel from a natural history dataset.
GlobeNewsWire • Nov 9, 2026

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Management will host a conference call and webcast at 4:30 p.m.
GlobeNewsWire • Nov 3, 2026

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
Capricor Therapeutics NASDAQ: CAPR presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration.
MarketBeat • Oct 7, 2026

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Seeking Alpha • Oct 8, 2026

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).
GlobeNewsWire • Oct 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Capricor Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.